Schizophrenia: all 3,539 studies

Page 8 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.

• A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)CompletedNCT02634346Phase 3Results posted
• A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With SchizophreniaCompletedNCT02634320Phase 4Results posted
• Aerobic Exercise for Cognition in SchizophreniaCompletedNCT02621983Not applicableResults posted
• Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable SchizophreniaTerminatedNCT02614586Phase 1Results posted
• A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy ParticipantsTerminatedNCT02566759Phase 1Results posted
• Improving Cognition in Schizophrenia Using tDCSCompletedNCT02539797Not applicableResults posted
• Person-Centered Versus Measurement-Based Care in Mental HealthCompletedNCT02507349Not applicableResults posted
• Cannabidiol Treatment in Patients With Early PsychosisCompletedNCT02504151Phase 2Results posted
• Target Engagement for Oxytocin: Dose Ranging StudyCompletedNCT02498236Not applicableResults posted
• Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual SchizophreniaCompletedNCT02477670Phase 2Results posted
• A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of SchizophreniaCompletedNCT02477020Phase 2Results posted
• Improving Negative Symptoms & Community Engagement in Veterans With SchizophreniaCompletedNCT02469389Not applicableResults posted
• A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of TreatmentCompletedNCT02469155Phase 3Results posted
• A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass SpectrometryTerminatedNCT02462473Phase 2Results posted
• Reducing Cardiovascular Risk in Adults With Serious Mental IllnessCompletedNCT02451670Not applicableResults posted
• A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic SchizophreniaTerminatedNCT02435836Phase 3Results posted
• A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or SchizophreniformCompletedNCT02431702Phase 3Results posted
• The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging StudyCompletedNCT02421146Not applicableResults posted
• Mobile Health Technology to Enhance Abstinence in Smokers With SchizophreniaCompletedNCT02420015Phase 4Results posted
• A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With SchizophreniaCompletedNCT02418819Phase 1Results posted
• Exenatide Weekly Injections as an Adjunctive Treatment in Patients With SchizophreniaCompletedNCT02417142Phase 4Results posted
• The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in ParanoiaCompletedNCT02408198Phase 2Results posted
• Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)CompletedNCT02404155Not applicableResults posted
• Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy VolunteersCompletedNCT02392468Phase 1Results posted
• Motivational Negative Symptoms in Schizophrenia: Intervention and BiomarkersCompletedNCT02386605Not applicableResults posted
• Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase SchizophrenicsCompletedNCT02360319Phase 4Results posted
• STimulation to Improve Auditory haLLucinationsCompletedNCT02360228Not applicableResults posted
• Long-term Study of DSP-5423P in Patients With SchizophreniaCompletedNCT02335658Phase 3Results posted
• Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700CompletedNCT02333487Phase 1Results posted
• Multiple Ascending Doses of PF-04958242 in Subjects With Stable SchizophreniaCompletedNCT02332798Phase 1Results posted
• Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserineCompletedNCT02304432Early Phase 1Results posted
• Confirmatory Study of DSP-5423P in Patients With SchizophreniaCompletedNCT02287584Phase 3Results posted
• A Trial to Assess the Antipsychotic Efficacy of ITI-007CompletedNCT02282761Phase 3Results posted
• A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.CompletedNCT02281773Phase 2Results posted
• Treating Refractory Schizophrenia With rTMSTerminatedNCT02242578Not applicableResults posted
• Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and MetabolismCompletedNCT02237417Phase 4Results posted
• Effect of MMFS-202-302 on Cognitive Enhancement in SchizophreniaCompletedNCT02237235Phase 2Results posted
• Galantamine and Memantine Combination for Cognitive Impairments in SchizophreniaTerminatedNCT02234752Phase 2Results posted
• Novel Smoking Cessation Drug for SchizophreniaCompletedNCT02230384Phase 2Results posted
• A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With SchizophreniaCompletedNCT02220712Phase 1Results posted
• Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral AripiprazoleCompletedNCT02219009Phase 2Results posted
• Long Term Study of RBP 7000 in the Treatment of Subjects With SchizophreniaCompletedNCT02203838Phase 3Results posted
• Lurasidone Effects on Tissue Glutamate in SchizophreniaCompletedNCT02199743Phase 4Results posted
• Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With ImpulsivityCompletedNCT02194933Phase 3Results posted
• Fixed Dose Intervention Trial of New England Enhancing Survival in SMI PatientsCompletedNCT02188121Phase 4Results posted
• Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)CompletedNCT02181803Phase 1Results posted
• Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human SubjectsCompletedNCT02174523Phase 1Results posted
• A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy SubjectsCompletedNCT02174510Phase 1Results posted
• Improving Negative Symptoms of Psychosis In Real-world EnvironmentsCompletedNCT02170051Not applicableResults posted
• A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic SchizophreniaCompletedNCT02164981Phase 2Results posted
• A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderCompletedNCT02161718Phase 2Results posted
• D-serine and Cognitive Remediation in SchizophreniaCompletedNCT02156908Phase 2Results posted
• Open-label Study of the Efficacy of Intranasal Oxytocin in SchizophreniaTerminatedNCT02144155Not applicableResults posted
• Effects of Metformin and Fish Oil on Treatment With ClozapineTerminatedNCT02140788Phase 4Results posted
• rTMS in First Episode PsychosisCompletedNCT02131129Not applicableResults posted
• Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in SchizophrenicCompletedNCT02128919Not applicableResults posted
• Minocycline Augmentation to ClozapineCompletedNCT02124811Phase 4Results posted
• Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal ActivityCompletedNCT02118610Not applicableResults posted
• Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia PatientsCompletedNCT02109562Phase 3Results posted
• Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in SchizophreniaCompletedNCT02104752Phase 1/2Results posted
• Pharmacokinetics and Tolerability Study of Risperidone ISM® in SchizophreniaCompletedNCT02086786Phase 2Results posted
• Randomized Controlled Trial (RCT) of a Motivational Decision Support SystemCompletedNCT02086162Not applicableResults posted
• A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and HomelessnessCompletedNCT02085447Not applicableResults posted
• Roflumilast Plus Antipsychotics Proof of Mechanism Study in SchizophreniaCompletedNCT02079844Phase 1Results posted
• Nicotinic Enhancement of Cognitive Remediation Training in SchizophreniaCompletedNCT02069392Not applicableResults posted
• Tryptophan MRI in People With Schizophrenia and Healthy ControlsCompletedNCT02067975Phase 2/3Results posted
• Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute SchizophreniaCompletedNCT02054702Phase 3Results posted
• Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental IllnessCompletedNCT02035202Not applicableResults posted
• Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of SchizophreniaCompletedNCT02034474Phase 4Results posted
• Biomarkers in First Episode SchizophreniaCompletedNCT02033382Results posted
• Comparison of E-health vs. In-person Multi-Family Group (MFG)CompletedNCT02032680Not applicableResults posted
• Project Bridge: Peer Health Navigator InterventionCompletedNCT02022462Not applicableResults posted
• Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode SchizophreniaCompletedNCT02013622Phase 3Results posted
• A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase SchizophreniaCompletedNCT02008773Phase 2Results posted
• Acetylcholine, Tobacco Smoking, Genes and Nicotinic ReceptorsCompletedNCT02008292Not applicableResults posted
• A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic DisorderCompletedNCT02006628Phase 2Results posted
• A Clinical Trial of Lurasidone in Treatment of SchizophreniaCompletedNCT02002832Phase 3Results posted
• Building Employment Skills Through Therapy for VeteransCompletedNCT01992913Not applicableResults posted
• Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)CompletedNCT01992393Not applicableResults posted
• D-Cycloserine Augmentation of Cognitive Behavioral Therapy for DelusionsCompletedNCT01981759Phase 4Results posted
• Acceptance and Commitment Therapy for the Inpatient Treatment of PsychosisCompletedNCT01981356Early Phase 1Results posted
• Development of a Mobile System for Self-management of Schizophrenia (SOS)CompletedNCT01969500Not applicableResults posted
• Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?CompletedNCT01964404Phase 1Results posted
• Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in SchizophreniaCompletedNCT01963676Not applicableResults posted
• Aripiprazole Once-monthly in Patients With SchizophreniaCompletedNCT01959035Phase 3Results posted
• A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.CompletedNCT01955564Phase 1Results posted
• MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic MedicationsCompletedNCT01953237Not applicableResults posted
• A New Paradigm for Illness Monitoring and Relapse Prevention in SchizophreniaCompletedNCT01952041Not applicableResults posted
• Personalized and Scalable Cognitive Remediation ApproachesCompletedNCT01945333Not applicableResults posted
• A Short Treatment Study of Aripiprazole in Pediatric Patients With SchizophreniaCompletedNCT01942161Phase 2/3Results posted
• A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With SchizophreniaCompletedNCT01942148Phase 3Results posted
• Study of Repetitive Transcranial Magnetic Stimulation in the Treatment of Cognitive Impairment in SchizophreniaCompletedNCT01940939Not applicableResults posted
• An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of SchizophreniaTerminatedNCT01939548Phase 2Results posted
• Assessing the Effects of Fanapt® on Social Cognition in SchizophreniaTerminatedNCT01929889Phase 4Results posted
• Pediatric Open-Label Extension StudyCompletedNCT01914393Phase 3Results posted
• Antipsychotic Effects on Brain Function in SchizophreniaTerminatedNCT01913327Phase 4Results posted
• Translational Neuroscience Optimization of GlyT1 InhibitorCompletedNCT01911676Phase 2Results posted
• Pediatric Schizophrenia Efficacy and Safety StudyCompletedNCT01911429Phase 3Results posted
• Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With SchizophreniaCompletedNCT01909466Phase 1Results posted
• A Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT01903837Phase 2Results posted

← Schizophrenia overview